AcouSort enters collaboration agreement with a Belgian diagnostics company

Report this content

AcouSort has entered a partnership with a Belgian diagnostics company that develops innovative products for point-of-care testing. Together, the companies will develop a test platform based on AcouSort's technology to be used in the Belgian company's product development. The collaboration will initially generate revenues of 29,500 Euro in Q1-2021.

The Belgium-based company is developing a platform for point-of-care diagnostics based on whole blood, initially focusing on analysis of blood cells. In the long term, there are plans to develop the system to be able to analyze other fractions of blood samples. With the jointly developed test platform, the Belgian company will evaluate if AcouSort's technology for integrated blood separation can improve their system's measurement performance.

“We are very much looking forward to starting this exciting collaboration where our core technology will be evaluated for integration into an innovative diagnostic instrument for point-of-care testing. As previously mentioned, these types of collaborations are very important enablers for concluding OEM agreements in the long run. If the outcome is positive, we have good hopes that this may lead to a more long-term OEM collaboration,” says AcouSort’s CEO Torsten Freltoft.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO
Telephone: +45 2045 0854

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.